Table 3.
Comparisons between the Z0011 Cohort and the MD Anderson Cancer Center Breast-Conserving Therapy Cohort
| Characteristic | n (%)
|
p Value | |
|---|---|---|---|
| Z0011 Cohort (n = 856) | MDACC BCT cohort (n = 449) | ||
| Clinical T stage | 0.02* | ||
| T1 | 587 (69.3) | 340 (75.7) | |
| T2 | 260 (30.7) | 109 (24.3) | |
| No. of adjuvant treatments | 0.05* | ||
| ≥1 | 826 (96.5) | 442 (98.4) | |
| 0 | 30 (3.5) | 7 (1.6) | |
| Nuclear grade | <0.0001 | ||
| I | 152 (23.8) | 58 (12.9) | |
| II/III | 487 (76.2) | 391 (87.1) | |
| Presence of LVI | 0.5* | ||
| No | 397 (62.1) | 303 (67.5) | |
| Yes | 242 (37.9) | 146 (32.5) | |
| Hormone receptor status | 0.2* | ||
| ER+/PR+ | 526 (67.9) | 319 (71.2) | |
| ER+/PR− | 115 (14.8) | 73 (16.3) | |
| ER−/PR+ | 7 (0.9) | 3 (0.7) | |
| ER−/PR− | 127 (16.4) | 53 (11.8) | |
| Lymph node metastasis diameter | 0.8 | ||
| Micrometastasis (>0.2–2.0 mm) | 301 (33.8) | 156 (34.7) | |
| Macrometastasis (>2.0 mm) | 590 (66.2) | 293 (65.3) | |
*
Fisher’s exact test.
ER, estrogen receptor; LVI, lymphovascular invasion; MDACC, MD Anderson Cancer Center; PR, progesterone receptor; BCT, breast-conserving therapy.